Featured Research

from universities, journals, and other organizations

Urgent need for Alzheimer's drug development identified: 99.6 percent of drug attempts fail

Date:
July 3, 2014
Source:
Cleveland Clinic
Summary:
Researchers have conducted the first-ever analysis of clinical trials for Alzheimer's disease, revealing an urgent need to increase the number of agents entering the AD drug development pipeline and progressing successfully towards new therapy treatments.

Researchers at the Cleveland Clinic Lou Ruvo Center for Brain Health have conducted the first-ever analysis of clinical trials for Alzheimer's disease (AD), revealing an urgent need to increase the number of agents entering the AD drug development pipeline and progressing successfully towards new therapy treatments. The paper, "Alzheimer's Disease Drug Development Pipeline: Few Candidates, Frequent Failures," was published today in the journal Alzheimer's Research & Therapy.

A comprehensive look at all clinical trials underway shows:

  • There are relatively few drugs in development for Alzheimer's disease.
  • The failure rate for AD drug development is 99.6 percent for the decade 2002-2012.
  • The number of drugs has been declining since 2009.

"Our goal was to examine historical trends to help understand why Alzheimer's disease treatment development efforts so often fail," said Jeffrey L. Cummings, M.D., ScD, Director of the Cleveland Clinic Lou Ruvo Center for Brain Health. "With an estimated 44 million people living worldwide with the condition, the study shows that the Alzheimer's disease drug development ecosystem needs more support given the magnitude of the problem."

Using the advanced search mechanisms of ClinicalTrials.gov, a government website that records all ongoing clinical trials, Dr. Cummings, along with Kate Zhong, M.D., Senior Director of Clinical Research and Development, and Touro University medical student Travis Morstorf, constructed a comprehensive analysis to examine all trials since 2002.

"By analyzing both completed as well as on-going trials and currently active compounds, we were able to provide insight into longitudinal trends in drug development," said Dr. Zhong. "What we found was that the investment in AD drugs and therapies is relatively low compared to the challenge posed by the disease. The pipeline is almost dry."

This comprehensive analysis illustrates the high rate of failure of compounds and the need for a constant supply of new drugs or a higher focus on repurposing, which can be assessed for efficacy in AD. With AD more expensive to the U.S. economy than cardiovascular disease or cancer, the Lou Ruvo Center for Brain Health research team believes the system of AD drugs must be supported, grown and coordinated to improve the success rate and development of new therapies.

In order to accelerate the drug development process and reduce the need to constantly invent new drugs, researchers note the need for more repositioning studies, which involve studying an already-approved drug in a new use or condition. For example, researchers at the Cleveland Clinic Lou Ruvo Center for Brain Health are leading a landmark Phase IIa clinical trial to determine if bexarotene (Targretin™), a drug currently FDA approved to treat skin cancer, can remove a protein build-up in the brains of Alzheimer's patients, as it did in a recent animal study.


Story Source:

The above story is based on materials provided by Cleveland Clinic. Note: Materials may be edited for content and length.


Cite This Page:

Cleveland Clinic. "Urgent need for Alzheimer's drug development identified: 99.6 percent of drug attempts fail." ScienceDaily. ScienceDaily, 3 July 2014. <www.sciencedaily.com/releases/2014/07/140703102647.htm>.
Cleveland Clinic. (2014, July 3). Urgent need for Alzheimer's drug development identified: 99.6 percent of drug attempts fail. ScienceDaily. Retrieved September 18, 2014 from www.sciencedaily.com/releases/2014/07/140703102647.htm
Cleveland Clinic. "Urgent need for Alzheimer's drug development identified: 99.6 percent of drug attempts fail." ScienceDaily. www.sciencedaily.com/releases/2014/07/140703102647.htm (accessed September 18, 2014).

Share This



More Health & Medicine News

Thursday, September 18, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

The Cost of Ebola

The Cost of Ebola

Reuters - Business Video Online (Sep. 18, 2014) — As Sierra Leone prepares for a three-day "lockdown" in its latest bid to stem the spread of Ebola, Ciara Lee looks at the financial implications of fighting the largest ever outbreak of the disease. Video provided by Reuters
Powered by NewsLook.com
What HealthKit Bug Means For Your iOS Fitness Apps

What HealthKit Bug Means For Your iOS Fitness Apps

Newsy (Sep. 18, 2014) — Apple has delayed the launch of the HealthKit app platform, citing a bug. Video provided by Newsy
Powered by NewsLook.com
Residents Vaccinated as Haiti Fights Cholera Epidemic

Residents Vaccinated as Haiti Fights Cholera Epidemic

AFP (Sep. 18, 2014) — Haitians receive the second dose of the vaccine against cholera as part of the UN's vaccination campaign. Duration: 00:34 Video provided by AFP
Powered by NewsLook.com
Artificial Sweetener Could Promote Diabetes

Artificial Sweetener Could Promote Diabetes

Newsy (Sep. 17, 2014) — Doctors once thought artificial sweeteners lacked the health risks of sugar, but a new study says they can impact blood sugar levels the same way. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins